Cannabis Potency Labels Changed Few Health Perceptions in a College Survey Experiment

Changing a product description is not the same as changing a person's drug exposure. Two experiments involving college students tested health perceptions of different THC/CBD descriptions, not the biological safety of those products.

Participants evaluated described products

The research included 2,047 young adults across separate flower and edible experiments. Participants were randomly assigned descriptions of THC-dominant, CBD-dominant or equal THC/CBD products and answered questions about perceived benefits, risks and willingness to use or purchase.

Most comparisons were nonsignificant

For flower, the CBD-dominant description produced a modest difference in an overall health judgment. The abstract reports no other significant effects for the stated benefit, risk, purchase or use comparisons. The pattern was not moderated by reported cannabis use status or tolerance.

Perception is the endpoint

These findings describe how participants interpreted the information presented. They do not show that different formulations have equivalent pharmacology or health consequences. A nonsignificant survey comparison cannot erase known differences between dose, route, timing or cannabinoid composition.

For communication, the study suggests that simply naming THC and CBD proportions may not reliably produce sharply differentiated judgments in this population. Whether a label is understood must be assessed separately from whether its contents are accurately measured. The selected college-student sample and hypothetical product decisions also limit conclusions about older adults, patients and real purchasing behavior. An opinion about safety should remain separate from clinical evidence of safety.

Related: interpreting cannabis tolerance claims.

Research cited

Magnan RE; Ladd BO; Pearson MR; Addictions Research Team. Perceived effects of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) content on cannabis-related health risks and benefits. Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors (2026). doi:10.1037/adb0001159. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

An Endogenous Pain Pathway Worked Independently of Endocannabinoid Mechanisms in Rodents

A rodent study found pain-related benefits from activating an endogenous adenosine pathway independently of opioid and endocannabinoid mechanisms. Endogenous pain modulation is therefore not automatically evidence of cannabinoid-receptor involvement. The intervention targeted adenosine signaling Researchers increased endogenous adenosine through kinase inhibition and separately tested a selective A3-receptor agonist. Receptor blockade…

Spread the love

Read Article: An Endogenous Pain Pathway Worked Independently of Endocannabinoid Mechanisms in Rodents

Cannabis in a Mixed-Drug Fatality Series: Hair and Blood Answer Different Exposure Questions

A Danish methadone-fatality study reported extensive mixed-drug exposure, including cannabis, and used segmental hair analysis to extend the exposure history beyond blood testing. That additional history was not proof of simultaneous intoxication from every listed substance. The two matrices supplied different information The study examined fatalities with both blood and…

Spread the love

Read Article: Cannabis in a Mixed-Drug Fatality Series: Hair and Blood Answer Different Exposure Questions

A Refractory Cancer-Pain Review’s Cannabinoid Option Was Not an Evidence-Based Ranking of Add-On Treatments

A 2015 review included cannabinoids among options for refractory cancer pain while describing weak benefit evidence across the reviewed drug strategies. Inclusion on a treatment-options list did not establish superiority or a favorable outcome for every patient. Refractory pain was a specific clinical question The review concerned pain not adequately…

Spread the love

Read Article: A Refractory Cancer-Pain Review’s Cannabinoid Option Was Not an Evidence-Based Ranking of Add-On Treatments

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us